LivaNova Enters into Definitive Agreement to Divest Its Cardiac Rhythm Management Business Franchise

Register to receive a free Cardiac Rhythm Management Market Report Suite for Europe synopsis and brochure

LivaNova PLC announced that it has entered into a definitive Stock and Asset Purchase Agreement (“Purchase Agreement”) to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation (“MicroPort”). LivaNova and MicroPort executed and delivered the Purchase Agreement, pursuant to the terms of a binding Letter of Intent, previously announced on November 20, 2017.

The announcement follows the successful completion of works council information and consultation requirements in France. The proposed transaction is subject to customary regulatory and other closing conditions. The transaction is expected to close in the second quarter of 2018.

About LivaNova

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. LivaNova’s advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. Headquartered in London, LivaNova has a presence in more than 100 countries worldwide. The Company currently employs more than 4,500 employees, inclusive of approximately 900 employed by our CRM business franchise. LivaNova operates as three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management, with operating headquarters in Mirandola (Italy), Houston (U.S.A.) and Clamart (France), respectively.

Source: https://www.businesswire.com/news/home/20180308005059/en/LivaNova-Enters-Definitive-Agreement-Divest-Cardiac-Rhythm

For Further Information

More on the cardiac rhythm management market in Europe can be found in a series of reports published by iData entitled the Europe Market Report Suite for Cardiac Rhythm Management. This report covers the following market segments: implantable cardioverter defibrillators (ICDs), pacemakers, cardiac resynchronization therapy (CRT) devices and cardiac leads.

The iData series on the market for cardiac rhythm management devices covers the U.S. and 15 countries in Europe including Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands and Luxemburg), Scandinavia (Finland, Denmark, Sweden and Norway), Portugal, Austria and Switzerland. Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about cardiac rhythm management market data or procedure data, register online or email us at [email protected] for an Europe Market Report Suite for Cardiac Rhythm Management brochure and synopsis.

close-link
close-link
close-link

Subscribe to MedTech Market News - Get exclusive analyst articles, monthly newsletters and iData offers

close-link
close-link